SPECIAL FEATURES

CCR Translations

6645 The Context of Blood Vessels and Response to VEGF-Targeted Therapy
Brian I. Rini
See related article, p. 6943

CCR Perspectives in Drug Approval

6650 Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

CCR Drug Updates

6657 Pralatrexate Pharmacology and Clinical Development
Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O’Connor

Molecular Pathways

6662 Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
Lorena Fontán and Ari Melnick

Perspectives

6669 Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?
Anita Sveen, Arild Nesbakken, Trude H. Aasen, Marianne G. Guren, Kjell M. Tveit, Rolf L. Skotheim, and Ragnhild A. Lothe

HUMAN CANCER BIOLOGY

6686 Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeça, Maria Calaminici, and John G. Gribben

6678 Hepatocellular Carcinoma from an Immunologic Perspective
Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

6680 BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

6696 HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaojie Meng, Rachel Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jinzhong Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

CANCER THERAPY: PRECLINICAL

6716 Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagyembek Manap, Linlin Xiao, Jiaoyu Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Rashaan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6853</td>
<td>The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy</td>
<td>Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao</td>
</tr>
<tr>
<td>6863</td>
<td>Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis</td>
<td>Carlo Palmieri, John R. Fullarton, and Janet Brown</td>
</tr>
<tr>
<td>6873</td>
<td>Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia</td>
<td>Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, and Maryalice Stetler-Stevenson</td>
</tr>
<tr>
<td>6882</td>
<td>Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma</td>
<td>Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kweek, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jie Xin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes</td>
</tr>
<tr>
<td>6912</td>
<td>Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors</td>
<td>David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorang Liang, Robert L. Yauch, Thomas O'Brien, Richard Bourgon, Hartmut Koeppe, and Lisa D. Belmont</td>
</tr>
<tr>
<td>6924</td>
<td>The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer</td>
<td>Kevin Sharpe, Grant D. Stewart, Alan Mackay, Christophe Van Neste, Charlotte Rofe, Dan Berny, Irfan Kayani, Axl Bex, Elaine Wan, Flach C. O'Mahony, Marie O'Donnell, Simon Chowdhury, Rukma Doshi, Colin Ho-Yen, Marco Gerlinger, Dawn Baker, Neil Smith, Barry Davies, Anju Sader, Ekaterini Boleti, Tim De Meyer, Wim Van Criekinge, Luis Beltran, Yong-Jie Lu, David J. Harrison, Andrew R. Reynolds, and Tom Powles</td>
</tr>
<tr>
<td>6935</td>
<td>Large-scale Analysis of PDGFRα Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib</td>
<td>Jie Dai, Yan Kong, Lu Si, Zhuhong Chi, Chuanliang Cui, Xian Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, and Jun Guo</td>
</tr>
<tr>
<td>6957</td>
<td>Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)</td>
<td>Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, and Herbert L. Hurwitz for the Alliance for Clinical Trials in Oncology</td>
</tr>
</tbody>
</table>
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial


Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodriguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andrés Cervantes, Josep Tabernero, Premal Patel, and José Baselga

Acknowledgment to Reviewers

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.
Clinical Cancer Research

19 (24)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/24

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.